Background: This study aimed to compare fecal calprotectin (FC) levels with other commonly used parameters as part of patient care during evaluation for inflammatory bowel disease (IBD).
Methods: We recruited adult IBD patients with ulcerative colitis (UC) and Crohn's disease (CD) and compared the results of the patient's biopsy results (i.e., inflamed versus noninflamed) for six sites (i.e., ileum, ascending colon, transverse colon, descending colon, sigmoid colon, rectum) with concentrations of C-reactive protein (CRP), total leucocytes and fecal calprotectin (FC).
Results: We found that FC was significantly elevated in a concentration-dependent manner that correlated with the number of active inflammation sites reported in biopsy. Although CRP and leucocyte measurements trended upwards in line with inflammation reported from biopsy, the results were highly variable and highlighted poor reliability of these biomarkers for indicating IBD inflammation.
Conclusions: These results strongly suggest that FC correlates best with biopsy reports and is a superior marker than CRP and leucocytes.
Keywords: Bowel biopsy; Fecal calprotectin; Inflammatory bowel disease; c-reactive protein.
© The Author(s) 2020. Published by Oxford University Press on behalf of the Canadian Association of Gastroenterology.